Joseph R Pisegna
Overview
Explore the profile of Joseph R Pisegna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
1272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fansiwala K, Lewis M, Pisegna J
Am J Gastroenterol
. 2024 Nov;
120(1):5-8.
PMID: 39569875
No abstract available.
2.
Shera S, Katzka W, Yang J, Chang C, Arias-Jayo N, Lagishetty V, et al.
Front Microbiol
. 2024 Aug;
15:1407555.
PMID: 39184030
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly 25% of the population and is the leading cause for liver-related mortality. Bariatric surgery is a well-known treatment for MASLD and...
3.
Mederos M, Court C, Dipardo B, Pisegna J, Dawson D, Hines O, et al.
J Surg Oncol
. 2024 Aug;
130(5):1070-1077.
PMID: 39155697
Background: Pancreatic neuroendocrine tumors (pNETs) are genomically diverse tumors. The management of newly diagnosed well-differentiated pNETs is limited by a lack of sensitivity of existing biomarkers for prognostication. Our goal...
4.
Benhammou J, Sinnett-Smith J, Pisegna J, Rozengurt E
Gastro Hep Adv
. 2024 Aug;
2(2):232-241.
PMID: 39132609
Nonalcoholic fatty liver disease has reached pandemic proportions with one of its most consequential complications being hepatocellular carcinoma (HCC). Nonalcoholic fatty liver disease-related HCC is becoming the leading indication for...
5.
Adeniran E, Yadav D, Pandol S, Papachristou G, Buxbaum J, Pisegna J, et al.
Gastro Hep Adv
. 2024 Aug;
3(1):61-63.
PMID: 39132171
No abstract available.
6.
Lee S, Garske K, Arasu U, Kar A, Miao Z, Alvarez M, et al.
EBioMedicine
. 2024 Jul;
106:105232.
PMID: 38991381
Background: Abdominal obesity increases the risk for non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: To elucidate the directional cell-type level biological mechanisms...
7.
Yang J, Chittajallu P, Benhammou J, Patel A, Pisegna J, Tabibian J, et al.
Dig Dis Sci
. 2024 Jun;
69(8):3079-3084.
PMID: 38896359
Background: Treatment with atezolizumab and bevacizumab has become standard of care for advanced unresectable hepatocellular carcinoma (HCC) but carries an increased gastrointestinal bleeding risk. Therefore, patients are often required to...
8.
Jeon C, Adeniran E, Stewart C, Papachristou G, Pisegna J, Kuc A, et al.
Pancreatology
. 2023 Aug;
23(7):761-766.
PMID: 37567847
Background/objective: Alcohol consumption is increasing in women, who more frequently report abdominal symptoms compared to men. We aimed to examine differences in presentation of acute pancreatitis [AP] in male and...
9.
10.
Vu J, Luong L, Sanford D, Oh S, Kuc A, Pisegna R, et al.
Biology (Basel)
. 2023 Jul;
12(7).
PMID: 37508442
The overwhelming increase in the prevalence of obesity and related disorders in recent years is one of the greatest threats to the global healthcare system since it generates immense healthcare...